Leerink Partners Reiterates Outperform Rating on Spyre (SYRE): 'today's update reflects SYRE's strong clinical execution'
Tweet Send to a Friend
Leerink Partners analyst Thomas J. Smith reiterated an Outperform rating and $49.00 price target on Spyre (NASDAQ: SYRE)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
